Clay Siegall, M.D., is the president, the co-founder and the CEO of Seattle Genetics. This biotech company has grown to become an important player in the fight against cancer, and it has only gotten stronger since its birth. Cancer research is very time consuming as well as very demanding. Fighting deadly diseases isn’t easy, but Seattle Genetics’ antibodies have done an amazing job with eradicating cancer. This company develops some of the very best antibody-based therapies, which provides targeted-fighting actions against cancer. Being so advanced, the medications can attach themselves to cancer cells and then inject the cancer cells with a proprietary blend of cocktails.
Dr. Siegall is an old guard of the industry. He employs three major principles into the company’s program. This includes rigorous research, drug development and scientific innovation. The scientific part comes from Dr. Siegall’s scientific background. With Siegall at the leadership position, this company currently boasts a $10 billion-market value. Seattle Genetics has nearly 1,000 employees, which makes it one of the Pacific Northwest’s biggest job producers. The company’s dull, beige buildings might not seem too high-tech, but the company’s magic comes from within these hallowed walls. Graduating from biotech to large pharma is another goal of Seattle Genetics as well as another goal of Dr. Siegall. Instead of selling its equity to a much larger pharmaceutical company, Siegall is looking to build this company into its own cancer research powerhouse. By controlling the rights to the company’s own international-marketing campaigns, Seattle Genetics will surely reach its goals in a matter of time.
Since its birth in 1998, Seattle Genetics has been making waves throughout the industry. Of course, it has seen some hard times, but it was able to pick itself-up by the bootstraps to continue with great success.